Bulgaria · Delayed Price · Currency is EUR Sopharma AD Statistics
Total Valuation
Sopharma AD has a market cap or net worth of EUR 1.79 billion. The enterprise value is 2.07 billion.
| Market Cap | 1.79B |
| Enterprise Value | 2.07B |
Important Dates
The next confirmed earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jul 9, 2026 |
Share Statistics
Sopharma AD has 538.41 million shares outstanding. The number of shares has decreased by -25.97% in one year.
| Current Share Class | 538.41M |
| Shares Outstanding | 538.41M |
| Shares Change (YoY) | -25.97% |
| Shares Change (QoQ) | +1.05% |
| Owned by Insiders (%) | 9.85% |
| Owned by Institutions (%) | 0.28% |
| Float | 178.22M |
Valuation Ratios
The trailing PE ratio is 14.59.
| PE Ratio | 14.59 |
| Forward PE | n/a |
| PS Ratio | 1.23 |
| PB Ratio | 3.23 |
| P/TBV Ratio | 4.38 |
| P/FCF Ratio | 49.94 |
| P/OCF Ratio | 29.36 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.49, with an EV/FCF ratio of 57.74.
| EV / Earnings | 24.30 |
| EV / Sales | 1.42 |
| EV / EBITDA | 14.49 |
| EV / EBIT | 20.38 |
| EV / FCF | 57.74 |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.43 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 2.30 |
| Debt / FCF | 8.00 |
| Interest Coverage | 7.28 |
Financial Efficiency
Return on equity (ROE) is 17.20% and return on invested capital (ROIC) is 9.27%.
| Return on Equity (ROE) | 17.20% |
| Return on Assets (ROA) | 4.98% |
| Return on Invested Capital (ROIC) | 9.27% |
| Return on Capital Employed (ROCE) | 12.23% |
| Weighted Average Cost of Capital (WACC) | 4.81% |
| Revenue Per Employee | 240,229 |
| Profits Per Employee | 14,059 |
| Employee Count | 6,049 |
| Asset Turnover | 1.39 |
| Inventory Turnover | 4.39 |
Taxes
In the past 12 months, Sopharma AD has paid 9.10 million in taxes.
| Income Tax | 9.10M |
| Effective Tax Rate | 9.34% |
Stock Price Statistics
The stock price has increased by +136.97% in the last 52 weeks. The beta is 0.14, so Sopharma AD's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | +136.97% |
| 50-Day Moving Average | 2.48 |
| 200-Day Moving Average | 2.01 |
| Relative Strength Index (RSI) | 88.53 |
| Average Volume (20 Days) | 39,117 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sopharma AD had revenue of EUR 1.45 billion and earned 85.04 million in profits. Earnings per share was 0.23.
| Revenue | 1.45B |
| Gross Profit | 357.81M |
| Operating Income | 83.38M |
| Pretax Income | 97.48M |
| Net Income | 85.04M |
| EBITDA | 115.34M |
| EBIT | 83.38M |
| Earnings Per Share (EPS) | 0.23 |
Balance Sheet
The company has 24.54 million in cash and 286.49 million in debt, with a net cash position of -261.95 million or -0.49 per share.
| Cash & Cash Equivalents | 24.54M |
| Total Debt | 286.49M |
| Net Cash | -261.95M |
| Net Cash Per Share | -0.49 |
| Equity (Book Value) | 554.08M |
| Book Value Per Share | 1.00 |
| Working Capital | 171.59M |
Cash Flow
In the last 12 months, operating cash flow was 60.87 million and capital expenditures -25.08 million, giving a free cash flow of 35.80 million.
| Operating Cash Flow | 60.87M |
| Capital Expenditures | -25.08M |
| Depreciation & Amortization | 31.95M |
| Net Borrowing | -50.32M |
| Free Cash Flow | 35.80M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 24.62%, with operating and profit margins of 5.74% and 5.85%.
| Gross Margin | 24.62% |
| Operating Margin | 5.74% |
| Pretax Margin | 6.71% |
| Profit Margin | 5.85% |
| EBITDA Margin | 7.94% |
| EBIT Margin | 5.74% |
| FCF Margin | 2.46% |
Dividends & Yields
This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 4.22%.
| Dividend Per Share | 0.14 |
| Dividend Yield | 4.22% |
| Dividend Growth (YoY) | 80.70% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 35.71% |
| FCF Payout Ratio | 145.90% |
| Buyback Yield | 25.97% |
| Shareholder Yield | 30.19% |
| Earnings Yield | 6.85% |
| FCF Yield | 2.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2025. It was a forward split with a ratio of 3.
| Last Split Date | Jul 10, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Sopharma AD has an Altman Z-Score of 3.04 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.04 |
| Piotroski F-Score | 6 |